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Abstract
Poly(ADP-ribose) Polymerase-13 (PARP13/ZAP/ZC3HAV1) is an antiviral factor, active against 
specific RNA viruses such as MLV, SINV and HIV. During infection, PARP13 binds viral RNA 
via its four CCCH-type zinc finger domains and targets it for degradation by recruiting cellular 
mRNA decay factors such as the exosome complex and XRN1. Here we show that PARP13 binds 
to and regulates cellular mRNAs in the absence of viral infection. Knockdown of PARP13 results 
in the misregulation of hundreds of transcripts. Among the most upregulated transcripts is 
TRAILR4 that encodes a decoy receptor for TRAIL - a pro-apoptotic cytokine that is a promising 
target for the therapeutic inhibition of cancers. PARP13 destabilizes TRAILR4 mRNA 
posttranscriptionally in an exosome dependent manner by binding to a region in its 3’UTR. As a 
consequence, PARP13 represses TRAILR4 expression and increases cell sensitivity to TRAIL-
mediated apoptosis, acting as a key regulator of the cellular response to TRAIL.
Poly(ADP-ribose) Polymerase-13 (PARP13), also known as Zinc Finger Antiviral Protein 
(ZAP), ARTD13, and ZC3HAV1, is a member of the PARP family of proteins – enzymes 
that modify target proteins with ADP-ribose using nicotinamide adenine dinucleotide 
(NAD+) as substrate1. Two PARP13 isoforms are expressed constitutively in human cells: 
PARP13.1 is targeted to membranes by a C-terminal CaaX motif, whereas PARP13.2 is 
cytoplasmic1, 2. Both proteins are unable to generate ADP-ribose - PARP13.1 contains a 
PARP domain lacking key amino acid residues required for PARP activity whereas the 
entire PARP domain is absent in PARP13.21. Both isoforms of PARP13 contain four N-
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terminal RNA binding CCCH-type Zinc Fingers - domains found in proteins that function in 
the regulation of RNA stability and splicing such as tristetraprolin (TTP) and muscleblind-
like (MBNL1), respectively3–6.
PARP13 was originally identified in a screen for antiviral factors3. It binds RNAs of viral 
origin during infection and targets them for degradation via the cellular mRNA decay 
machinery7–9. Several RNA viruses, including MLV, SINV, HIV and EBV as well as the 
RNA intermediate of the Hepatitis B DNA virus have been shown to be targets of 
PARP133, 7, 8, 10–12. How viral RNA is detected by PARP13 is currently not known, and 
although binding to PARP13 is a requirement for viral RNA degradation, no motifs or 
structural features common to the known targets have been identified13. Structure analysis 
of the PARP13 RNA binding domain suggests that PARP13 binds looped RNA, therefore 
target recognition could involve structural features rather than linear sequence motifs6.
PARP13 binds to multiple components of the cellular 3’-5’ mRNA decay machinery 
including polyA-specific ribonuclease (PARN), and subunits of the exosome exonuclease 
complex, RRP46/EXOSC5 and RRP42/EXOSC78, 9. Recruitment of these decay factors 
results in the 3’-5’ cleavage of viral RNAs bound to PARP13. Although 5’-3’ RNA decay 
has also been shown to play a role in PARP13-mediated viral degradation, proteins involved 
in this process including the decapping factors DCP1 and DCP2 and the 5’-3’ exonuclease 
XRN1, do not bind to PARP13 directly and are instead recruited by other PARP13 binding 
partners such as DDX178.
Whether or not PARP13 binds to and modulates cellular RNAs either in the absence or 
presence of viral infection is unknown. However several indications point towards a role for 
PARP13 in cellular RNA regulation: 1) both PARP13 isoforms are expressed at high levels 
in cells, however only PARP13.2 expression is upregulated during viral infection suggesting 
that PARP13.1 has functions unrelated to the antiviral response1, 14; 2) even in the absence 
of viral infection, PARP13 localizes to RNA rich stress granules – non-membranous 
ribonucleoprotein structures that form during cellular stress in order to sequester mRNAs 
and inhibit their translation15; 3) PARP13 regulates the miRNA pathway by targeting 
Argonaute proteins for ADP-ribosylation and this regulation occurs both in the absence and 
in the presence of viral infection15, 16. This suggests that PARP13 targeting of RNA to 
cellular decay pathways could also occur in the absence of viral infection, and that PARP13 
could therefore function as a general regulator of cellular mRNA.
Here we show that PARP13 binds to and regulates cellular RNA in the absence of viral 
infection, and that its depletion results in significant misregulation of the transcriptome with 
an enrichment in signal peptide containing transcripts and immune response genes. From the 
list of PARP13-dependent differentially expressed genes we focused this study on 
understanding how PARP13 regulates TRAILR4 - a member of a family of transmembrane 
receptors composed of TRAILR1–417, 18 that bind to TRAIL, a proapoptotic TNF-family 
cytokine. We show that PARP13 destabilizes TRAILR4 mRNA posttranscriptionally but has 
no effect on the levels of other TRAIL receptors. It binds to a specific fragment in the 3’ 
untranslated region (3’UTR) of TRAILR4 mRNA, and leads to its degradation via the RNA 
exosome complex.
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Primary cells are TRAIL resistant; however many transformed cells become sensitive to 
TRAIL induced apoptosis, making it an attractive target for the therapeutic treatment of 
cancers17. TRAIL binding to TRAILR1 and TRAILR2 triggers the assembly of the Death 
Inducing Signaling Complex (DISC)19, 20 leading to the recruitment and activation of 
caspase-8 and induction of the extrinsic apoptotic pathway19, 20. In contrast TRAILR3 and 
TRAILR4 act as prosurvival decoy receptors that bind TRAIL but cannot assemble 
functional DISCs and therefore cannot signal apoptosis21, 22. The relative expression of each 
receptor varies in different cancers and tissue types and is thought to be important for the 
overall cellular response to TRAIL23. Accordingly, high levels of these decoy receptors can 
prevent TRAIL induced cells death and likely contribute to acquired TRAIL resistance in 
cancer cells24. By repressing TRAILR4 expression PARP13 acts a key regulator of the 
cellular response to TRAIL and depletion of PARP13 results in TRAILR4 protein 
accumulation and TRAIL resistance in multiple cell lines.
PARP13 binds to cellular RNA
To determine if PARP13 binds to cellular RNA, we performed crosslinking 
immunopreciptation (CLIP) in HeLa cells using affinity purified PARP13 antibody. A 
strong signal from bound, crosslinked RNA that collapsed to two major bands at high RNase 
concentrations was identified (Fig. 1a). The collapsed signal migrated at the molecular 
weight of PARP13.1 and 13.2, and was PARP13-specific since it was not detected in similar 
purifications performed in PARP13−/− HeLa cell lines generated using zinc finger nucleases 
(Fig. 1a, Supplementary Fig. 1). Since PARP13.1 and PARP13.2 are constitutively 
expressed in HeLa cells, we compared the binding of cellular RNA to each isoform using N-
terminal streptavidin-binding protein (SBP) fusions. SBP-PARP13.1 and SBP-PARP13.2 
bound similar amounts of RNA and the signal for both was RNAse sensitive confirming the 
attached molecules as RNA (Fig. 1b, 1c). For both the endogenous PARP13 and the SBP 
precipitations no signal was identified when UV cross-linking was omitted demonstrating 
the specificity of the reactions (Fig. 1d). To further confirm that binding of RNA to PARP13 
is specific and requires the CCCH zinc fingers, we generated deletions of these domains 
from PARP13.1 and PARP13.2 and performed CLIP (PARP13.1ΔZnF and PARP13.2 ΔZnF) 
(Fig. 1e, 1f). Deletion of these domains resulted in dramatic reduction of signal.
Structural analysis of the PARP13 RNA binding domain containing four CCCH zinc fingers 
identified key amino acid residues for viral RNA binding6. Two cavities, defined by V72, 
Y108, F144 (Cavity 1) and H176, R189 (Cavity 2) are thought to be important for RNA 
binding. We mutated each residue of Cavity 1, multiple residues in Cavity 2, and all five 
residues found in both cavities to alanine in SBP-PARP13.1 and assayed the mutants for 
RNA binding using CLIP (Fig. 1e, 1g). Mutation of all five residues to generate 
PARP13.1VYFHR reduced RNA binding to negligible levels and mutation of all three Cavity 
1 residues resulted in a similar decrease in RNA binding as individual mutations of each 
Cavity 2 residue (Fig. 1g, 1h).
It is possible that the reduction in RNA binding in the mutants was a result of aggregation or 
mislocailzation of the mutant proteins. To test this, we compared the localization of 
PARP13.1ΔZnF and PARP13.1VYFHR to wild type protein in HeLa cells. Both mutants 
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exhibited localization patterns similar to PARP13.1 (Fig. 2). We also examined localization 
of the mutant proteins to stress granules. We previously showed that PARP13 is highly 
enriched in stress granules, structures that are assembled during cytoplasmic stress and 
contain high concentrations of cellular mRNA15. PARP13.1 properly localized to stress 
granules upon sodium arsenite treatment, however both PARP13.1ΔZnF and 
PARP13.1VYFHR failed to localize to these structures15, 25,(Fig. 2, Supplementary Fig. 2). 
This defective targeting was even more striking for PARP13.2ΔZnF and PARP13.2VYFHR 
(Fig. 2 Supplementary Fig. 2). These results confirm that the mutants are defective in 
binding RNA and that this defect affects cellular function. They further suggest that binding 
to cellular RNA is critical for PARP13 localization to stress granules.
PARP13 regulates the transcriptome
To determine if PARP13 regulates cellular RNA we analyzed the transcriptome in the 
absence of PARP13. We used Agilent microarrays to compare the relative abundance of 
transcripts in HeLa cells transfected with control siRNA to cells transfected with PARP13-
specific siRNA (Fig. 3a, Supplementary Data X). Depletion of PARP13 resulted in 
significant misregulation of the transcriptome with 1841 out of a total of 36338 transcripts 
analyzed showing >0.5 Log2 fold change (Log2FC) relative to control knockdowns (1065 
upregulated and 776 downregulated transcripts). Of these, 85 transcripts exhibited 
Log2FC>1 relative to control siRNAs (66 upregulated and 19 downregulated). In total 73 
transcripts passed a significance threshold of p<0.05 (moderated t-statistic with Benjamini 
Hochberg adjustment) (Table 1).
The 50 upregulated transcripts with a p-value <0.05 showed enrichment for genes containing 
a signal peptide required for targeting of mRNA for translation at the endoplasmic reticulum 
(ER) (analyzed with the Database for Annotation, Visualization and Integrated Discovery 
(DAVID)26, Enrichment Score 3.4, p-value<0.0001; Supplementary Data X), suggesting 
that PARP13 could regulate transcripts at the ER. The membranous perinuclear localization 
we observed for PARP13.1 (Fig. 2) and the previously reported membrane targeting of this 
protein2 suggested a potential enrichment at the ER. We therefore costained exogenously 
expressed PARP13 isoforms with the ER marker ER Tracker, and observed colocalization 
with PARP13.1 but not PARP13.2. This localization is independent of RNA binding since 
PARP13.1VYFHR localized very similarly to the wild type protein (Fig. 3b). Targeting of 
PARP13 to the ER may therefore be one mechanism of regulating its function and its RNA 
target specificity. Gene Set Enrichment Analysis27 of the same genes identified enrichment 
for members of the interferon immune response pathway (p-value<0.0001, Normalized 
Enrichment Score = 2.22) (Supplementary Fig. 3, Supplementary Data X).
To verify our results, we analyzed 6 of the top 10 most upregulated transcripts using 
quantitative real-time reverse-transcription PCR (qRT-PCR) in both PARP13 knockdowns 
and PARP13−/− cells. All 6 transcripts were upregulated relative to controls upon PARP13 
depletion (Fig. 3c). With the exception of TRAILR4/TNFRSF10D, each of these genes 
encodes an immune response gene and is a member of the interferon-stimulated genes 
(ISGs), activated in response to interferon signaling. The upregulation of the five ISGs 
appears to be specific and is not the result of a general activation of the interferon response 
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since JAK-STAT signaling was not increased in the knockdown or knockout cells (Fig. 3d) 
and since other canonical ISGs (IRFs, TRIMS, IFITMs) were not upregulated in our 
transcriptome analysis (Supplementary Data X). Interestingly, like PARP13, the upregulated 
ISGs (OASL, IFIT2, IFIT3) function in inhibition of viral replication and translation28 
suggesting that their upregulation could be a compensatory mechanism for PARP13 
depletion.
To identify the direct targets of PARP13 regulation among the 6 highly upregulated 
transcripts, we compared their expression levels in PARP13−/− cells relative to PARP13−/− 
cells expressing wild type PARP13 or PARP13 RNA-binding mutant. While both PARP13.1 
and PARP13.2 are constitutively expressed in HeLa cells, PARP13.2 expression increases 
during viral infection in an interferon dependent manner, whereas PARP13.1 expression 
does not14. Therefore to exclude interferon-related effects we focused our experiments on 
PARP13.1. Direct targets of PARP13 binding and regulation would in theory decrease upon 
PARP13.1 but not PARP13VYFHR expression in PARP13−/− cells. TRAILR4 mRNA clearly 
behaved in this manner with a 40% decrease in transcript levels upon PARP13.1 expression 
and no change upon PARP13.1VYFHR expression (Fig. 3e). This analysis proved difficult for 
the remaining 5 transcripts since transient plasmid transfection induced a transcriptional 
upregulation of these ISGs as previously shown29.
PARP13 represses TRAILR4 mRNA and protein expression
Due to its biological importance and the clinical interest in TRAIL we examined the role of 
PARP13 in the regulation of TRAILR4 expression and how that regulation might impact 
TRAIL signaling and apoptosis. Upregulation of TRAILR4 mRNA in PARP13-depleted 
HeLa cells had a direct effect on TRAILR4 protein expression: TRAILR4 protein levels, 
barely detectable in wild type HeLa cells, increased in PARP13 knockdown cells and in all 
three independently isolated PARP13−/− cell lines (Fig. 4a, 4b). In addition, consistent with 
our results identifying TRAILR4 as a direct target of PARP13 regulation (Fig. 3e, 
Supplementary Fig. 4), expression of PARP13.1, but not PARP13.1VYFHR, in PARP13−/−A 
cells was sufficient to reduce TRAILR4 protein expression (Fig. 4c). PARP13 repression of 
TRAILR4 mRNA represents a general mechanism of TRAILR4 regulation in multiple 
human cell types. In all cell lines tested, including primary cells such as Tert immortalized 
Retinal Primary Epithelial (RPE1) cells and transformed cells such as human colon 
HCT116, human colon adenocarcinoma SW480 and HeLa cells, TRAILR4 mRNA levels 
increased upon PARP13 depletion identifying suppression of TRAILR4 expression as an 
important physiological function of PARP13 (Fig. 4d). Under physiological conditions, the 
primary isoform of PARP13 that regulates TRAILR4 is PARP13.1 since specific 
knockdown of PARP13.1 in HeLa cells increased TRAILR4 mRNA to levels similar to 
those obtained upon total PARP13 depletion (Fig. 4e).
PARP13 inhibits TRAILR4 posttranscriptionally via its 3’UTR
The PARP13.1 and PARP13.1VYFHR rescue assays performed in PARP13−/− cells suggest 
that TRAILR4 regulation by PARP13 is posttranscriptional and requires RNA binding to 
PARP13 (Fig. 3e, Supplementary Fig. 4). Posttranscriptional regulation was confirmed by 
Todorova et al. Page 5
Nat Commun. Author manuscript; available in PMC 2015 May 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
analyzing the upregulated TRAILR4 transcripts via qRT-PCR with primers that overlap 
intron-exon boundaries to identify unspliced pre-mRNA, and primers that overlap exon-
exon boundaries, to identify mature transcripts. PARP13 knockdown resulted in increased 
amounts of mature TRAILR4 mRNA, but had no effect on the amount of pre-mRNA, 
suggesting that TRAILR4 transcription is not altered upon PARP13 depletion and that 
regulation of TRAILR4 by PARP13 is posttranscriptional (Fig. 5a). Since 
posttranscriptional regulation of mRNA often occurs via the 3’ untranslated region (3’UTR) 
we designed reporter constructs containing the 3’UTR of TRAILR4 or GAPDH (as negative 
control) fused to Renilla luciferase in the psiCHECK2 vector. This vector also encodes 
Firefly luciferase as a transfection control. Renilla-TRAILR4 3’UTR expression was 
decreased ~20% in HeLa cells relative to PARP13−/− cells whereas no significant difference 
in Renilla or Renilla-GAPDH 3’UTR expression was detected between the two cell lines 
(Fig. 5b). Together these results suggest that PARP13 destabilizes TRAILR4 
posttranscriptionally via its 3’UTR.
Computational analysis of the TRAILR4 3’UTR identified 7 putative AU rich elements 
(ARE) known to destabilize RNA30, 31, one conserved miRNA binding site that is muscle 
specific (miR-133abc)32,33, and 4 short and poorly characterized ZAP responsive elements 
(ZRE) predicted by SELEX to mediate PARP13 recognition of RNA targets13 (Fig. 5c, 
Supplementary Fig. 5). To identify the key PARP13 dependent regulatory sequences in the 
TRAILR4 3’UTR, we designed truncations of the TRAILR4 3’UTR and fused them to 
Renilla luciferase in the psiCHECK2 vector (Fig. 5c). Fragments were designed based on a 
secondary structure prediction of the TRAILR4 3’UTR to avoid disturbing high-probability 
RNA folds34 (Supplementary Fig. 6). The relative PARP13-dependent destabilization of 
each fragment was determined by subtracting expression in wild type cells from expression 
in PARP13−/− cells (Fig. 5c, Supplementary Fig. 7). This analysis identified nucleotides 
516–1115 of the 3’UTR as necessary for PARP13 regulation. Fusion of nucleotides 516–
1115 (Fragment E) to Renilla resulted in destabilization of the construct in wild type cells, 
confirming that this sequence contains the relevant signal for PARP13-dependent repression 
(Fig. 5c). This fragment includes 2 ZREs and 2 AREs, including one that contains multiple 
overlapping ARE sequences suggesting that PARP13 regulation of TRAILR4 mRNA might 
require ARE and/or ZRE recognition. Our analysis also suggests that TRAILR4 regulation is 
likely miRNA independent since no predicted miRNA binding sites are found in the 
TRAILR4 regulatory sequence.
PARP13 binds TRAILR4 mRNA
To determine if PARP13 regulation of TRAILR4 occurs via direct binding to TRAILR4 
mRNA, we performed CLIP qRT-PCR in cells expressing SBP-PARP13.1, SBP-
PARP13.1VYFHR or PARP13.1ΔZnF and electrophoretic mobility shift assays (EMSA) using 
purified SBP-PARP13.1 or SBP-PARP13.1VYFHR and 32P labeled Fragment E or Fragment 
1 as control. CLIP qRT-PCR analysis identified significant enrichment of TRAILR4 mRNA 
in wild type PARP13.1 precipitations relative to PARP13.1VYFHR or PARP13.1ΔZnF 
confirming a direct and specific binding interaction between TRAILR4 mRNA and PARP13 
in vivo (Fig. 5d, 5e). These results were confirmed in vitro by EMSA assays where SBP-
PARP13.1 bound to Fragment E with high affinity (Kd=123nM) and to Fragment 1 with 
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lower affinity (Kd=508nM). PARP13.1VYFHR failed to bind either fragment (Fig. 5f). These 
experiments demonstrate the specificity of TRAILR4 mRNA binding to PARP13 and show 
that the regulatory region of the TRAILR4 3’UTR binds directly to PARP13 with good 
selectivity (Fig. 5f).
PARP13 destabilization of TRAILR4 mRNA is exosome dependent
PARP13 regulates viral RNA stability via XRN1-dependent 5’-3’ decay, and exosome-
dependent 3’-5’ decay8. PARP13 can also bind to and modulate Argonaute (Ago) activity, 
critical for miRNA dependent posttranscriptional regulation of mRNA stability15. To 
determine if TRAILR4 mRNA stability is regulated through any of these pathways, 
TRAILR4 mRNA levels were examined upon knockdown of Ago2, XRN1 or EXOSC5, an 
exosome complex component shown to bind PARP139. Knockdown of EXOSC5, verified 
by qRT-PCR (antibodies were non-reactive), resulted in stabilization of TRAILR4 mRNA in 
HeLa cells suggesting that exosome function is necessary for regulation of TRAILR4 
mRNA (Fig. 6a, 6b). In contrast, neither XRN1 knockdown in HeLa cells nor depletion of 
Ago2 in HEK293 cells using tetracycline-inducible Ago2 shRNA35 resulted in obvious 
TRAILR4 mRNA stabilization (Fig. 6a, 6b, 6c). PARP13 depletion in the Ago2 shRNA 
inducible cell lines resulted in similar levels of TRAILR4 upregulation regardless of Ago2 
depletion, further suggesting that Ago2 function is not necessary for TRAILR4 regulation by 
PARP13 (Fig. 6c).
To determine if exosome or XRN1 activity is required for PARP13 dependent 
destabilization of TRAILR4 mRNA, we examined the expression of psiCHECK2 reporter 
constructs encoding Renilla and Renilla-TRAILR4 3’UTR in wild type and PARP13−/− cells 
transfected with control, EXOSC5 or XRN1 siRNA (Fig. 6d). Relative PARP13-dependent 
destabilization was then calculated by subtracting the Renilla/Firefly luciferase signal 
obtained from wild type cells from the signal obtained from PARP13−/− cells (Fig. 6d). 
Knockdown of EXOSC5 resulted in a pronounced defect in the ability of PARP13 to repress 
TRAILR4 3’UTR with a 15% relative destabilization of the construct compared to 40% in 
control knockdowns. Knockdown of XRN1 resulted in milder but potentially relevant 
defects with a 30% relative destabilization of the Renilla-TRAILR4 3’UTR compared to 
40% in controls consistent with the observation that exosome activity was the primary 
pathway regulating endogenous TRAILR4 mRNA (Fig. 6a). We therefore conclude that 
PARP13 requires exosome activity, and potentially XRN1, to destabilize TRAILR4 mRNA 
(and likely other PARP13 targets).
PARP13 decreases TRAILR4 mRNA half life
Since the exosome complex is a key regulator of mRNA decay, we examined the TRAILR4 
mRNA decay rate in PARP13−/− and wild type cells. Newly transcribed RNA was pulse-
labeled with 4-thiouridine and labeled transcripts purified at specific time points after 4-
thiouridine removal. qRT-PCR was then performed on the purified transcripts to quantitate 
amounts of TRAILR4 mRNA and GAPDH mRNA. ACTB mRNA was used to normalize 
inputs. TRAILR4 mRNA decay rates were significantly higher in wild type cells (t1/2=1.5 h) 
than in PARP13−/− cells (t1/2=13 h) whereas GAPDH decay rates were similar in both cell 
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lines (Fig. 6e). Together our data is consistent with a model in which PARP13 facilitates 
efficient degradation of TRAILR4 mRNA via the activity of the exosome complex (Fig. 6a, 
6d) and suggest that PARP13 functions as a novel RNA binding protein that regulates 
cellular RNA stability by binding to the 3’UTR.
PARP13 depletion inhibits TRAIL-induced apoptosis
To investigate the physiological relevance of TRAILR4 regulation by PARP13 we examined 
TRAIL induced apoptotic signaling upon PARP13 depletion. TRAILR4 expression levels 
are a key regulator of TRAIL sensitivity in certain cancers18, 24. HeLa cells are TRAIL 
sensitive due to low TRAILR4 expression and exogenous expression of TRAILR4 is 
sufficient to confer TRAIL resistance21, 24 (Fig. 7a). Of the four TRAIL receptors, only 
TRAILR4 expression is regulated by PARP13 - TRAILR4 mRNA expression, examined by 
qRT-PCR, and protein levels, assayed by immunoblot, were increased in PARP13−/− 
relative to wild type cells, whereas no differences in protein and mRNA levels of TRAILR1-
R2 were identified between PARP13−/− and wild type cells, and TRAIL-R3 protein could 
not be detected in this cell type, consistent with previous reports (Supplementary Fig.8, Fig. 
7b)21.These results suggest that by modulating TRAILR4 expression PARP13 could directly 
regulate the cellular response to TRAIL. We examined this possibility by assaying TRAIL 
induced apoptosis upon PARP13 depletion in TRAIL sensitive HCT116, SW480 and HeLa 
cells. Consistent with the increase in TRAILR4 mRNA levels (Fig. 4d), PARP13 
knockdown resulted in a pronounced resistance to TRAIL treatment in each of these cell 
types identifying PARP13 as a key regulator of the TRAIL response in these cell lines (Fig. 
7c). The newly acquired TRAIL resistance was a specific result of increased TRAILR4 
expression upon PARP13 knockdown since simultaneous knockdown of PARP13 and 
TRAILR4 in HeLa cells resulted in wild type TRAILR4 mRNA levels and TRAIL 
sensitivity profiles similar to control knockdowns (Fig. 7c, 7d).
The TRAIL resistance conferred by PARP13 inhibition can be permanently acquired. 
PARP13−/− cells were resistant to both short-term (24 h, Fig. 7e, 7f) and long term TRAIL 
treatment (7 days, Fig. 7g), suggesting that one mechanism of TRAIL resistance in cancers 
could be inhibition of PARP13 function. TRAIL resistance in PARP13−/− cells was 
completely reversed by expression of PARP13.1 but not PARP13.1VYFHR or 
PARP13.1ΔZnF, suggesting that the TRAIL resistance in these cells results from the lack of 
TRAILR4 mRNA regulation by PARP13 (Fig. 7h, 7i). Together these results suggest that 
PARP13 is necessary and sufficient to regulate the cellular response to TRAIL in cancer 
cells that are TRAIL sensitive in a manner dependent on TRAILR4 expression.
PARP13 depletion abrogates DISC assembly and function
TRAILR4 expression levels are important for TRAIL sensitivity in certain cancers due to 
the receptor’s ability to sequester TRAIL from TRAILR1 and R2 binding resulting in 
decreased DISC assembly and apoptotic signaling at these receptors upon TRAIL treatment. 
This apoptotic signaling is mediated by caspase-8, which is recruited to the DISC where it is 
activated and autoprocesses itself. Thus caspase-8 cleavage can be used to directly report on 
caspase-8 enzymatic activity. To determine if the TRAIL resistance observed in PARP13−/− 
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cells results from attenuated apoptotic signaling at the TRAIL receptor level, time-
dependent caspase-8 processing was analyzed in wild type or PARP13−/−A cells treated with 
TRAIL. Whereas caspase-8 was processed in HeLa cells resulting in the appearance of 
p43/p41 and p18 fragments, no such processing was observed in PARP13−/− cells, 
demonstrating an ablation of DISC signaling (Fig. 8a). A consistent upregulation of both 
PARP13.1 and PARP13.2 was observed upon TRAIL treatment suggesting positive 
feedback signaling (Fig. 8a). To determine if DISC assembly itself is defective in 
PARP13−/− cells we compared assembly to wild type cells using standard DISC 
precipitation assays that utilize epitope tagged TRAIL36. Recruitment of TRAILR1, 
TRAILR2 and caspase-8 to the DISC was greatly diminished in PARP13−/− cells relative to 
wild type (Fig. 8b). Together these results suggest that the TRAIL resistance found upon 
PARP13 depletion is due to defective DISC assembly, decreased caspase-8 activation and 
decreased apoptotic signaling from TRAIL receptors.
Discussion
In this manuscript we show that PARP13 binds cellular RNA and that its depletion results in 
significant misregulation of the transcriptome with an enrichment in signal peptide 
containing transcripts and immune response genes. We identify the mRNA encoding 
TRAILR4 as the first experimentally verified cellular target of PARP13 repression and 
demonstrate that PARP13 destabilizes TRAILR4 mRNA posttranscriptionally by binding to 
its 3’UTR and targeting it for degradation via the exosome complex. Consistent with these 
data, PARP13 depletion markedly alters TRAILR4 mRNA decay kinetics. By repressing 
TRAILR4 expression in the cell, PARP13 shifts the balance in the TRAIL signaling 
pathway towards decreased anti-apoptotic signaling and sensitizes cells to TRAIL-mediated 
apoptosis (Fig. 8c).
Expression of decoy receptors has been described as one mechanism of TRAIL resistance in 
cancer17, 36. Our results suggest that PARP13 could have important functions in regulating 
TRAIL resistance and that modulation of PARP13 may have the potential to overcome 
TRAILR4 mediated TRAIL resistance. This approach could improve the efficacy of TRAIL 
therapies currently in clinical trials to target multiple cancers37. Furthermore, it was recently 
shown that PARP1/2 inhibitors result in transcriptional upregulation of TRAILR2 and 
subsequent apoptosis in acute myeloid leukemias38. It therefore appears that the cellular 
response to TRAIL is regulated by multiple PARPs via transcriptional and 
posttranscriptional mechanisms.
Several important questions remain regarding PARP13 function in the regulation of cellular 
mRNA- what are the direct targets of regulation, how is target specificity determined, and 
does the regulation of cellular targets change upon viral infection? With the exception of 
TRAILR4, many of the transcripts misregulated upon PARP13 knockdown identified in this 
work are likely indirect targets. To better understand the biology of PARP13, identifying 
additional direct targets will be critical. Based on previous research on the selectivity of viral 
RNA binding to PARP13, target recognition of cellular mRNA is more likely to be mediated 
by structural features rather than linear sequence motifs, therefore it is unlikely that a 
consensus sequence will be identified6, 13. Interestingly, the expanded AU-rich element in 
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the TRAIILR4 3’UTR is predicted to form a hairpin with high probability (Supplementary 
Fig.5), suggesting that it may represent a structure recognized by PARP1334.
The highly significant enrichment of signal peptide containing transcripts upon PARP13 
depletion (corrected p-value<0.0001) strongly suggests that PARP13 has a specific function 
in the regulation of transmembrane proteins, or those that are destined to be secreted. This 
enrichment might be related to PARP13.1 localization at the ER. Indeed, PARP13.1 has 
been shown to be farnesylated, and this modification targets PARP13.1 to membranes and is 
required for its antiviral activity2. It is therefore possible that similar targeting of PARP13.1 
to membranes might also regulate its function in destabilizing cellular transcripts, including 
those at the ER.
It is important to note that PARP13 is just one member of the CCCH PARP subfamily 
identified based on the presence of CCCH RNA binding domains - PARP12 and PARP7 are 
the other two members1. Whereas PARP7 is poorly studied and little is known about its 
function, both PARP12 and PARP13 function in the antiviral response and localize to 
membraneous organelles (PARP13 to the ER and PARP12 to the Golgi)1, 39, 40. In addition, 
PARP12 and PARP13 exhibit similar domain structures including the presence of multiple 
tandem CCCH zinc fingers (vs only one in PARP7)1. Therefore PARP12 might also regulate 
cellular RNA in a manner similar to PARP13.
Methods
General
Experiments were performed in HeLa Kyoto cells unless otherwise stated. Knockdowns 
were performed using Lipofectamine 2000 as per manufacturer’s instructions with double 
transfections of 48 h. Exogenously expressed constructs were transfected using 
Lipofectamine 2000 for 24 h before the assay. Mutants were cloned using GeneString 
technology. TRAILR4 3’UTR was cloned from Origene clone SC117708 into psiCHECK2 
using Gene String technology. TRAILR4 3’UTR fragments were cloned by PCR 
amplification of the indicated regions and cloned into psiCHECK2. Renilla and Firefly 
luminescence were measured 48 h post transfection. Crosslinking followed by 
immunoprecipitation was performed as previously described41. To assess cell sensitivity to 
TRAIL-mediated apoptosis, cells were treated with TRAIL for 24 h, and cell viability was 
assayed by MTT assay (Millipore) or by Annexin V/PI flow cytometry (Biolegend) as per 
manufacturer’s instructions. Standard Western Blotting techniques were used, and full scans 
of important blots along with protein ladder markers are shown in Supplementary Fig. 9.
Cell culture and transfection
Cells were grown at 37 C and 5% CO2. HeLa Kyoto (ATCC), SW480 (a gift from Ryoma 
Ohi, Vanderbilt), and HEK293 (ATCC) cells were maintained in DMEM (Invitrogen) 
supplemented with 10% Fetal Bovine Serum (Life technologies); hTERT-RPE1 cells 
(ATCC) in Ham’s F12/DMEM (Mediatech) supplemented with 10% Fetal Bovine Serum 
and HCT116 cells (ATCC) were cultured in McCoy’s 5A (ATCC) supplemented with 10% 
Fetal Bovine Serum (Life technologies). For expression of recombinant proteins, HeLa cells 
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were transfected with Lipofectamine 2000 (Life Technologies) 24 h prior to assay. For 
RNAi, two 48 h transfections were performed with 20nM siRNA for Stealth siRNAs or 5nM 
for Silencer Select siRNAs using Lipofectamine 2000 according to the manufacturer’s 
protocol. For RPE1 RNAi, 5nM of siRNA was transfected with Silentfect (BioRad) 
following manufacturer protocols. IFNγ was from R&D Serotec, JAKi from Calbiochem 
and Flag-TRAIL from Axxora. His-TRAIL was purified according to standard procedures42.
PARP13 knockout cell lines
Zinc finger nucleases specific to the PARP13 genomic locus were purchased from Sigma 
Aldrich and transfected into HeLa Kyoto cells. Monoclonal cell lines (PARP13−/− A/B/C) 
were generated using serial dilution in 96 well plates, then tested for PARP13 expression via 
western blot. Three independent monoclonal cell lines lacking PARP13 expression were 
generated.
Cloning
GFP-PARP13 has been described previously1. To generate SBP-PARP13, GFP was 
substituted with streptavidin binding peptide tag using NheI and BspEI. PARP13 ΔZnF and 
PARP13 RNA binding point mutants were generated using GeneString (Invitrogen) flanked 
by XhoI/BstXI, which are internal sites in PARP13. PARP13ΔZnF features a deletion from 
nt228 to nt669.
The psiCHECK2 vector encoding Renilla and Firefly luciferase genes was purchased from 
Promega. TRAILR4 ORF was purchased from Origene (SC117708). A SalI site was 
introduced after the TRAILR4 stop codon using a Gene String flanked by PpuMI and ScaI, 
which are internal sites in TRAILR4 cDNA. The 3’UTR of TRAILR4 was then introduced 
downstream the Renilla luciferase in psiCHECK2 using SalI/XhoI and NotI digestion. 
psiCHECK2 + GAPDH 3’UTR is a kind gift from Dr. Benilde Jimenez. Truncations of 
TRAILR4 3’UTR were generated by PCR using primers with XhoI/NotI overhangs. 
psiCHECK2+TRAILR4 3’UTR was used as a template. Fragments were designed based on 
TRAILR4 3’UTR folding prediction (RNAFold) so as to preserve high-probability folding 
structures34.
Total RNA purification and Agilent microarrays
Total RNA purification was performed using Qiagen RNeasy Kit, following manufacturer 
instructions. Samples were labeled using the Two Color Quick Amp Labeling Kit (Agilent) 
following manufacturer protocol and hybridized on SurePrint G3 Human Gene Expression 
v2 8x60 microarray. Microarrays were scanned on SureScan Microarray Scanner (Agilent) 
and processed with Feature Extractor v10.5. Microarrays have been submitted to GEO, 
NCBI; accession number GSE56667.
CLIP
HeLa cells were UV crosslinked at 254 nm with 200mJ/cm2 (Stratagene Stratalinker). For 
endogenous PARP13 immunoprecipitation, cells were lysed in CLIP Lysis Buffer (1% 
NP-40, 0.1% SDS, 150mM NaCl, 1mM EDTA, 50mM TRIS (pH7.4), 1mM DTT), 
precleared at 16100 g, treated with RNaseA for 10min at 37 C, immunoprecipitated 
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overnight with PARP13 antibody and washed 2 X in CLIP Lysis buffer containing 1M 
NaCl. Bound RNA was labeled and detected according to Leung et al41. For SBP-PARP13 
precipitation, cells were UV crosslinked as described above, lysed with Cell Lysis Buffer 
(150mM NaCl, 50mM HEPES (pH7.4), 1mM MgCl2, 0.5% Triton, 1mM EGTA, 1mM 
DTT ), precleared at 16100 g, incubated with RNase A for 10 min at 37 C and bound to 
Streptavidin Sepharose beads (GE Healthcare). RNA bound to SBP-PARP13 was labeled 
according to Leung et al 41 and bound protein eluted with 4mM biotin.
CLIP qRT-PCR
Cells were UV-crosslinked at 254nM 200mV/cm2 and lysed in 1% Triton, 125mM KCl, 
1mM EDTA, 20mM HEPES pH7.9 under RNase-free conditions. SBP-PARP13 and 
PARP13 mutants were immunoprecipitated using Streptavidin Sepharose beads. After 
binding, beads were washed with lysis buffer supplemented with 10µ tRNA and 250mM 
KCl. Proteins were eluted in 4mM Biotin, treated with Proteinase K, and RNA was purified 
using Trizol, following manufacturer protocol. Input RNA was collected similarly from total 
lysate before the immunoprecipitation step. cDNA was prepared from input and bound RNA 
as described below.
qRT-PCR
cDNA was prepared using ViLo First Strand Kit (Life Technologies) and random primers.
1µg of total RNA or all CLIP–bound RNA was used per reaction. 100 ng of cDNA was used 
for each qRT-PCR reaction. Sybr Select reagent (Life Technologies) was used as directed 
and qRT-PCR was performed on a Roche 480 Light Cycler. Data analysis was performed as 
previously described43, using the ΔΔcT method. In all cases ACTB was used as a 
normalizing control. For gene-specific qRT-PCR primers used in this manuscript refer to 
table below.
Dual luciferase assays
HeLa cells were transfected with 50ng of psiCHECK2 constructs in 24-well plates. 48 h post 
transfection cells were lysed and lysates treated with the Pierce Renilla-Firefly Dual 
Luciferase Assay Kit as per instructions (Thermo Scientific). Firefly and Renilla 
luminescence was measured in white 96-well plates in a Tecan Plate Reader (Magenta and 
Green, 1000ms each). Renilla luminescence signal was normalized to Firefly signal for each 
well. For all figures bars represent averages of three individual 24-well plate wells; error 
bars represent standard deviation.
Cell staining and microscopy
Cells were split onto glass coverslips 16 h before treatment. To induce cytoplasmic stress, 
cells were incubated with 200µM sodium arsenite for 45 min at 37 C; control cells were left 
untreated. Unstressed cells were fixed in 4% formaldehyde for 30 min then extracted with 
Abdil 0.5% Triton for 25 min. Stressed cells were preextracted with HBS containing 0.1% 
Triton for 1min, then fixed in 4% Formaldehyde in HBS for 30min. Blocking and staining 
was performed as previously described1. Fixed cells were blocked in Abdil (4% BSA, 0.1% 
Triton in PBS), then incubated with antibodies diluted in Abdil for 45min each.
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Survival assay
For proliferation assays, 5000 cells were plated in 96 well plates and incubated with 
recombinant TRAIL the following day for 24 h. Proliferation was analyzed with the Cell 
Proliferation Kit II (Roche) according to the manufacturer’s instructions and survival was 
calculated by normalizing treated to untreated cells. For apoptosis assays, 40,000 cells were 
plated in 24 well plates and incubated with recombinant TRAIL for 24 h. Cells were 
harvested with Trypsin and stained with Annexin V-488 (Biolegend) and propidium-iodide 
(Sigma) in Annexin binding buffer (10mM HEPES, 140mM NaCl, and 2.5mM CaCl 2, pH 
7.4) for 15 min at RT. FACS analysis was performed on a FACScan instrument (BD) and 
cells negative for Annexin V and propidium iodide considered as alive. For colony forming 
assays, the indicated numbers of cells were plated in 12 well plates and grown for 7 days in 
medium with TRAIL changed every second day. Colonies were visualized by staining with 
0.02% crystal violet (Sigma) in 50% methanol.
Electrophoretic Mobility Shift Assays
SBP-PARP13.1 and SBP-PARP13.1VYFHR were purified from HEK293 cells lysed with 
Cell Lysis Buffer (CLB, 150mM NaCl, 50mM HEPES (pH7.4), 1mM MgCl2, 0.5% Triton, 
1mM EGTA, 1mM DTT ), precleared at 80000g, bound to Streptavidin Sepharose beads 
(GE Healthcare). Beads were washed with CLB containing 1M NaCl, and proteins were 
eluted with 4mM Biotin in CLB, then dialyzed overnight in 100mM KCl, 50mM TRIS, pH 
7.5. Protein concentrations were determined by Coomassie blue stain by comparison to a 
dilution series of BSA, and by UV spectrophotometry.
Fragment 1 and Fragment E were PCR-amplified, in-vitro transcribed using T7 RNA 
polymerase, purified and end-labeled with T4 Polynucleotide Kinase and 32P γATP as 
previously described 44.
EMSA binding reactions were performed for 1h at 20C in 10mM Tris, pH 7.5, 1mM EDTA, 
pH 8, 0.1M KCl, 0.1mM DTT, 5% vol/vol Glycerol, 0.01mg/ml BSA, 0.4units/µl RNAse 
inhibitor, 0.1 µg/ml tRNA with 2nM RNA and decreasing amounts of protein. Reactions 
were loaded onto 8% TBE Urea gels, and run in 0.5X TBE at room temperature, then 
exposed to phosphor screen and scanned.
To calculate Kd, bands were quantified using ImageJ, fraction bound was calculated, and 
data was fit to Hill’s equation using IGOR Pro.
4-thiouridine labeling and mRNA decay measurements
Wild type and PARP13−/−A cells were incubated with 200µM 4-Thioruridine for 2h, then 
growth media was changed and cells were collected immediately, and at two hour intervals 
for 8 h. Total RNA was Trizol extracted at each time point and newly transcribed RNA was 
biotin-labeled and purified as previously described 45. In brief, newly transcribed RNA was 
labeled with biotin-HPDP, RNA was repurified, and newly transcribed RNA was separated 
on streptavidin-coated magnetic beads (Miltenyi). RNA was eluted with 100mM DTT, and 
purified using MinElute Cleanup Kit (Qiagen).RT-qPCR was performed as described above. 
TRAILR4 and GAPDH levels were normalized to ACTB for each sample. Each time point 
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represents an average of three independent experiments; error bars show the standard 
deviation. Half life was calculated as previously described46. Half-life is an underestimate as 
expression levels are normalized to ACTB levels, which are also decreasing within this 
time-course (ACTB half life in HeLa cells is ~8h47.
DISC-IP
1×10^6 wild type or Parp13−/−A cells each were plated in two 10 cm plates for 2 days. Plates 
were washed once in DMEM (without FCS) and then incubated for 45 min in 2.5 ml DMEM 
without FCS and with or without 1µg/ml Flag-TRAIL (Axxora). After addition of 15ml cold 
PBS, cells were washed once with 15 ml cold PBS and scraped with a rubber policeman in 
1ml lysis buffer (30mM Tris/HCl pH7.4, 150mM NaCl, 5mM KCl, 10% Glycerol, 2mM 
EDTA and protease inhibitors). After addition of 100µl Triton X-100, lysates were rotated 
30 min at 4°C and harvested by centrifugation (45 min, 4°C, 15000g). The supernatant was 
removed, added to 20µl magnetic Protein-G beads (Invitrogen), washed three times in lysis 
buffer including Triton X-100 and rotated at 4 C overnight. After five washes in lysis buffer 
including Triton X-100, beads were heated at 75 C for 10 min in 20µl loading buffer, 
subsequently loaded on a gel and blotted for the indicated antibodies.
Caspase-8 processing
Wild type and PARP13−/− cells were plated in 6 wells and treated with His-TRAIL for the 
indicated time periods. Cells were harvested, lysed and analyzed by immunoblot with the 
indicated antibodies.
Reagents used in this manuscript
For reagents used please refer to Supplementary Table 1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PARP13 binds cellular RNA
a, Autoradiogram of PARP13 CLIP reactions performed using wild type (+/+) or PARP13-
null (−/−) cells treated with 1µg/ml or 0.13µg/ml RNaseA. Triangle indicates molecular 
weight (MW) of PARP13.1, circle indicates MW of PARP13.2. PARP13 immunoblot (IB) 
shown below. b, Autoradiogram of CLIP reactions from SBP-PARP13.1 and PARP13.2 
expressed and purified in wild type cells treated with 1µg/ml RNaseA. PARP13 
immunoblots shown below. c, Autoradiogram of SBP-PARP13.1 and SBP-PARP13.2 CLIP 
reactions treated with 1µg/ml or 0.1µg/ml RNase A. PARP13 immunoblots are shown 
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below. d, CLIP autoradiograms of endogenous PARP13, SBP-PARP13.1 and SBP-
PARP13.2 treated with 1µg/ml RNase A with or without UV crosslinking (254nm, 200mJ). 
PARP13 immunoblots shown below. e, Diagram of PARP13 isoforms and mutants. f, CLIP 
autoradiograms of SBP-PARP13.1, PARP13.1ΔZnF, PARP13.2 and PARP13.2ΔZnF 
precipitations treated with 1µg/ml RNase A. PARP13 immunoblot shown below. g, 
Autoradiogram of wild type and mutant PARP13.1 CLIP reactions. PARP13 immunoblot 
shown below (IB). Numerical values of 32P signal normalized to protein levels shown 
above; PARP13.1 RNA binding levels set to 1. h, Graph of 32P signals normalized to 
PARP13.1 protein levels for CLIP analysis shown in Fig. 1g.
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Figure 2. Localization of PARP13.1, PARP13.2 and RNA binding mutants
a, Immunofluorescence showing co-staining of exogenously expressed PARP13.1, 
PARP13.1ΔZnF, PARP13.1VYFHR, PARP13.2, PARP13.2ΔZnF or PARP13.2VYFHR in non-
stressed (No Treatment) and stressed (200µM Sodium Arsenite) cells. Scale Bar = 20µm.
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Figure 3. PARP13 depletion results in misregulation of the transcriptome
a, Volcano plot showing transcriptome-wide Log2 fold changes in mRNA expression in 
PARP13 knockdowns relative to control knockdowns obtained via Agilent array analysis of 
total mRNA (n=2 independent experiments). 6 of the Top 10 upregulated transcripts are 
labeled. The remaining mRNA data shown in the figure were obtained using qRT-PCR. b, 
Immunofluorescence of cell expressing SBP-PARP13.1, SBP-PARP13.1VYFHR or SBP-
PARP13.2, stained with anti-PARP13 and anti-SBP antibodies, and ER Tracker Red. In 
merge SBP signal is in green, ER Tracker signal is in red, PARP13 signal is not shown. 
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Scale bar = 20µm. c, Confirmation of CCL5, TRAILR4, OASL, IFIT2, RARRES3 and 
IFIT3 upregulation in PARP13 knockdown relative to control knockdown and in 
PARP13−/−A HeLa cells relative to wild type cells (n=3 independent experiments, bars 
represent SD) d, Left, Immunoblots of PARP13 and pSTAT1 in untransfected cells, or cells 
transfected with control or PARP13-specific siRNA, untreated or treated with 5µM Jak1 
inhibitor; right, immunoblots of PARP13 and pSTAT1 in wild type and PARP13−/− HeLa 
cells untreated or treated with 100units/ml IFNγ. GAPDH shown as loading control. e, 
mRNA levels of TRAILR4, CCL5, OASL, IFIT2, RARRES3 and IFIT3 in untransfected 
PARP13−/− cells and PARP13−/− cells expressing PARP13.1, PARP13.1VYFHR or GFP 
(DNA transfection control) relative to HeLa cells (n=3 independent experiments, bars 
represent SD).
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Figure 4. PARP13 repression of TRAILR4 mRNA and protein levels is dependent on its RNA 
binding
a, TRAILR4 mRNA and protein levels in PARP13 knockdown relative to control. GAPDH 
shown as loading control. n=3 independent experiments, error bars show SD. b, TRAILR4 
mRNA and protein levels in PARP13−/− cell lines relative to wild type cells. GAPDH shown 
as loading control. n=3 independent experiments, error bars show SD. c, TRAILR4 protein 
levels in wild type, PARP13−/−A, and PARP13−/−A cells expressing PARP13.1 or 
PARP13.1VYFHR. GAPDH shown as a loading control. d, TRAILR4 mRNA levels 
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(Log2FC) in PARP13 knockdown relative to control knockdown in RPE1, SW480 and 
HCT116 cells (averages of n=3 parallel reactions (RPE1) or n=3 independent experiments 
(SW480 and HCT116) shown, error bars show SD). Immunoblots show PARP13 
knockdown; GAPDH shown as normalizing control. e, TRAILR4 mRNA levels in cells 
treated with PARP13.1-specific and total PARP13 specific siRNAs relative to control 
siRNAs (averages of n=3 independent experiments shown, error bars show SD, p>0.05 
(n.s.), two-sided t-test comparing the two knockdowns). Immunoblots show PARP13.1 
depletion upon knockdown with PARP13.1 specific siRNA. GAPDH shown as loading 
control.
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Figure 5. PARP13 represses TRAILR4 mRNA posttranscriptionally by binding to a specific 
region in its 3’UTR
All RNA quantitation performed using qRT-PCR a, TRAILR4 mature RNA (Exon1/Exon3 
primer) and pre-mRNA (Intron6-Exon7, Intron 8/Exon9 primers) levels in PARP13 
knockdown relative to control knockdown (mean of n=3 independent experiments, error 
bars show SD). b, Normalized Renilla/Firefly luminescence for psiCHECK2 empty vector, 
psiCHECK2 expressing Renilla-GAPDH 3’UTR (GAPDH 3’UTR), and psiCHECK2 
expressing Renilla-TRAILR4 3’UTR (TRAILR4 3’UTR) expressed in wild type or 
PARP13−/−A cells (mean of n=3 independent experiments, error bars represent SD, p<0.01 
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(**), two sided t-test). c, Left top, diagram of Renilla-TRAILR4 3’UTR construct 
identifying AU-rich element (ARE), ZAP responsive element (ZRE), and miRNA binding 
sites for miR-133; triangle shading indicates relative length of motif- darker shades 
correspond to longer motifs. Specific ARE sequences and locations are shown in 
Supplementary Fig. 5. Left bottom, fragments used in 3’UTR destabilization assay. Blue 
fragments exhibited PARP13-dependent destabilization whereas red fragments were not 
regulated. Right, relative PARP13-dependent destabilization for each 3’UTR fragment, 
represented by fraction increase of normalized Renilla luminescence in PARP13−/−A cells 
relative to wild type cells, (means of n=3 independent experiments, error bars show SD, 
asterisks represent significance relative to empty vector, p<0.05 (*), p<0.01(**) and p<0.001 
(***), two-sided t-test) d, Fold enrichment (Log2) of TRAILR4 mRNA in input and bound 
fraction in PARP13.1 CLIP reactions relative to PARP13.1VYFHR reactions (mean of n=3 
independent experiments, error bars show SD, p<0.01 (**), two-sided t-test). PARP13 
immunoblot shows precipitated protein levels. e, Relative log2 levels of TRAILR4 mRNA 
in input and bound fractions in PARP13.1 CLIP reactions relative to PARP13.1ΔZnF 
reactions (averages of n=3 independent experiments, bars show SD, p<0.05 (*) relative to 
PARP13.1ΔZnF, two-sided t-test). PARP13 Immunoblot of precipitated protein shown at 
right. f, Electrophoretic Mobility Shift Assays (EMSA) of decreasing amounts of PARP13.1 
and PARP13.1VYFHR (from 533nM to 71nM, in 25% interval decrease) with radiolabeled 
Fragment E and Fragment 1 (experiment was repeated 3 times with similar results). Right, 
Coomassie stain showing equal protein concentration of PARP13.1 and PARP13.1VYFHR.
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Figure 6. PARP13 destabilization of TRAILR4 mRNA is exosome dependent
a, TRAILR4 mRNA levels in EXOSC5 and XRN1 knockdowns relative to control 
knockdown (means of n=3 independent experiments, bars show SD, asterisks represent 
significance relative to control siRNA, p<0.05 (*), p>0.05 (n.s.), two-sided t-test). b, Left, 
EXOSC5 mRNA levels in EXOSC5 knockdown relative to control knockdown (bars show 
SD, n=3 independent experiments); right, immunoblot showing XRN1 protein levels in 
control and XRN1 knockdown. GAPDH is shown as loading control. c, Relative TRAILR4 
mRNA levels in Tet-treated or untreated HEK293 cells expressing Tet-inducible Ago2 
shRNA, treated with control or PARP13-specific siRNA (averages of n=3 parallel reactions, 
error bars show SD). Immunoblots of PARP13, Ago2 and GAPDH (loading control) shown 
at right. d, Bar graphs showing normalized Renilla luminescence for empty vector and 
Renilla-TRAILR4 3’UTR, expressed in wild type (red) or PARP13−/−A cells (blue) treated 
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with control siRNA or siRNA specific for EXOSC5 or XRN1. PARP13-dependent 
destabilization levels, calculated by substracting normalized Renilla luminescence signal in 
wild type cells from signal in PARP13−/−cells, is shown at left of the bars. (means of n=3 
independent replicates, bars show SD, asterisks represent significance relative to control 
siRNA destabilization levels, p<0.001(***), p>0.05 (n.s). e, Decay of GAPDH mRNA and 
TRAILR4 mRNA is wild type and PARP13−/−cells measured by qRT-PCR of 4-thiouridine 
incorporated and purified RNA. At each time point GAPDH and TRAILR4 levels were 
normalized to ACTB levels. Levels at Time 0 were set as 0. (means of n=3 independent 
experiments, error bars show SD, asterisks represent significance relative to wild type levels 
for each time point, p<0.05(*), p<0.01(**), two-sided t-test).
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Figure 7. PARP13 depletion results in resistance to TRAIL-mediated apoptosis
a, Percent survival of untreated and TRAIL treated wild type cells and wild type cells 
expressing TRAILR4-Flag assayed via Annexin-V/PI FACS (average of n=3 independent 
experiments, bars represent SEM, p<0.05(*), two-sided t-test). b, Immunoblot of 
TRAILR1-2 and TRAILR4 proteins in wild type and PARP13−/−A cells. GAPDH is used as 
loading control. c, Survival assay measuring proliferation of SW480, HCT116 and HeLa 
cells with or without PARP13 knockdown after treatment with increasing concentrations of 
TRAIL for 24 h. Results are shown relative to untreated cells (means of n=3 independent 
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experiments, error bars show SEM). Results for double knockdown of TRAILR4 and 
PARP13 are shown for HeLa cells. d, TRAILR4 mRNA levels after PARP13 and 
PARP13+TRAILR4 knockdown relative to control knockdown (averages of n=3 
independent experiments, error bars show SD). e, Annexin-V/PI apoptosis assays comparing 
the percent survival of wild type and three independent PARP13−/− cell lines (A, B, C) upon 
1 µg/ml TRAIL treatment for 24 h (n=3 independent experiments, bars show SEM, asterisks 
show significance relative to wild type, p<0.001 (***), two-sided t-test) f, Normalized 
survival of wild type and three PARP13−/− cell lines treated with 1µg/ml TRAIL relative to 
untreated (averages of n=3 independent experiments, bars show SEM, asterisks show 
significance relative to wild type, p<0.05 (*) or p<0.01(**), two-sided t-test). g, Colony 
formation assay measured by crystal violet staining of wild type or PARP13−/−A cells 
treated with or without the indicated amounts of TRAIL for 7 days. h, Annexin-V/PI 
apoptosis assays comparing the percent survival of wild type, PARP13−/−A or PARP13−/−A 
cells expressing PARP13.1, PARP13.1VYFHR or PARP13.1ΔZnF upon treatment with or 
without 1 µg/ml TRAIL for 24 h. Data is shown as % survival (means of n=3 independent 
experiments, bars show SEM, asterisks show significance relative to wild type, p<0.05 (*), 
p<0.01(**), p>0.05 (n.s.), two-sided t-test). i, Normalized survival of wild type, 
PARP13−/−A cells and PARP13−/−A cells expressing PARP13.1, PARP13.1VYFHR or 
PARP13.1ΔZnF treated with 1µg/ml TRAIL relative to untreated (n=3 independent 
experiments, bars show SEM, asterisks represent significance relative to wild type, p<0.05 
(*), p<0.01(**), p<0.001(***), two-sided t-test).
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Figure 8. PARP13 depletion inhibits the formation of a functional DISC complex
a, Immunoblot examining caspase-8 cleavage at various time points after 1 µg/ml TRAIL 
treatment in wild type and PARP13−/− cells. Arrows indicate full-length (FL) caspase-8 and 
its cleavage products. GAPDH shown as loading control. b, Flag-TRAIL pulldown of the 
TRAIL-receptor complex in wild type and PARP13−/−A cells blotted for TRAILR1, R2 and 
caspase-8. Inputs for the reaction are also shown. c, Model of PARP13 dependent TRAILR4 
mRNA regulation and its effects on TRAIL mediated apoptosis.
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Table 1
PARP13 RNA binding mutants used in this manuscript
Mutant Mutations
PARP13.1ΔZnF Deletion AA 77–223
PARP13.1H H176A
PARP13.1R R189A
PARP13.1VYF V72A, Y108A, F144A
PARP13.1VYFHR V72A, Y108A, F144A, H176A, R189A
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Table 2
Number of differentially expressed transcripts upon PARP13.1 depletion
Cut-off Number of
genes
% of total Upregulated Downregulated
Log2FC>0.5 1841 5.066 1065 776
Log2FC>1 85 0.234 66 19
p-value<0.1 134 0.369 84 50
p-value<0.05 73 0.201 50 23
Log2FC>1 /
p-value<0.05
49 0.135 34 15
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